Profil
Carl Damiani served as the President and Chief Operating Officer of Transition Therapeutics, Inc. from 2015 to 2016.
Prior to that, he held positions at the same company from 2003 to 2016.
Anciens postes connus de Carl Damiani
| Sociétés | Poste | Fin |
|---|---|---|
| TRANSITION THERAPEUTICS INC | President | 01/12/2016 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Transition Therapeutics, Inc.
 Transition Therapeutics, Inc. Medical SpecialtiesHealth Technology Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada. | Health Technology |
